Bridging current knowledge gap: better primary colorectal cancer prevention in people living with metabolic dysfunction-associated steatotic liver

Excerpt

Trends of excessive and ectopic fat accumulation are continuously rising worldwide [1]. This metabolic disruption goes along with the epidemics of several noncommunicable diseases including obesity, insulin resistance, type 2 diabetes, and metabolic syndrome [2‐5]. In parallel, the prevalence of metabolic dysfunction-associated fatty liver disease (MASLD) is also increasing, and MASLD has become the most frequent chronic liver disease with heavy economic and clinical impacts globally [6, 7]. In addition, epidemiologic and pathophysiologic evidence links obesity, metabolic syndrome, and steatotic liver disease to several malignancies [8]. In this scenario, liver steatosis is no longer a simple “fellow traveler” with obesity and metabolic syndrome, but gains an active and independent role in increasing the risk of cancer onset both in the liver and in extra-hepatic organs [9, 10]. …